Rebound Acid Hypersecretion
Cross-source consensus on Rebound Acid Hypersecretion from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- Rebound acid hypersecretion is described as a central barrier to stopping PPIs. — Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients
- Gastrin levels rise during acid suppression. — Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients
- After PPI interruption, increased acid secretion may occur for up to 2 weeks. — Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients
- Rebound symptoms can lead patients to restart PPIs. — Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients
- Even asymptomatic volunteers may develop upper gastrointestinal symptoms after stopping PPIs following 4 to 8 weeks of treatment. — Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients